^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TT-702
i
Other names: TT-702, TT702, TT 702
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Cancer Research UK, Teon Therap
Drug class:
Adenosine A2B receptor antagonist
Related drugs:
6ms
CURATE: TT-702 in Patients With Advanced Solid Tumours. (clinicaltrials.gov)
P1/2, N=188, Recruiting, Cancer Research UK | N=114 --> 188 | Trial completion date: Sep 2025 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2027
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative
|
Nubeqa (darolutamide) • TT-702
over2years
CURATE: TT-702 in Patients With Advanced Solid Tumours. (clinicaltrials.gov)
P1/2, N=114, Recruiting, Cancer Research UK
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative
|
TT-702
Share via
